sevelamer

(redirected from Sevelamer hydrochloride)
Also found in: Dictionary.

sevelamer

 [sĕ-vel´ah-mer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease; administered orally.

sevelamer

/se·vel·a·mer/ (sĕ-vel´ah-mer) a phosphate-binding substance used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease.

sevelamer

[sĕvel′ahmer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease. It is administered orally.

sevelamer

A phosphate chelator used to reduce phosphorus in patients with end-stage renal disease and in chronic renal failure patients not requiring dialysis. It also reduces uric acid levels, and may be of use in patients with hyperuricaemia, uric acid nephrolithiasis and gout.

Adverse effects
Blood pressure lability (hypo- or hypertension), nausea, vomiting, dyspepsia, diarrhoea, constipation.

sevelamer

Renagel® Nephrology A chelator used to ↓ phosphorus in Pts with ESRD and in chronic renal failure Pts not requiring dialysis. See Chelation, End-stage renal disease.
References in periodicals archive ?
Lanthanum carbonate vs sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
ASN poster, "Influence Of Bile Acids On The Phosphate-Binding Efficacy Of Lanthanum Carbonate And Sevelamer Hydrochloride.
In the first part of the Phase 2 study, 34 ESRD patients who were taking approximately 6 to 15 tablets/capsules per day of calcium acetate, calcium carbonate, lanthanum carbonate or sevelamer hydrochloride or any combination of these agents were eligible for enrollment and immediately switched to a starting dose of 4.
Sevelamer hydrochloride is currently used by more than 350,000 patients worldwide.
Sevelamer hydrochloride provides the added benefit of significant LDL cholesterol reduction (32 percent).
Additionally, data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented at the 2007 spring clinical meeting of the National Kidney Foundation.
Data showing the equivalence of sevelamer carbonate and sevelamer hydrochloride were presented last week at the spring clinical meeting of the National Kidney Foundation.
Enrollment has been completed in a trial evaluating the product's equivalence to sevelamer hydrochloride for patients with end-stage renal disease.